HIV Citation List: March 29 - April 11, 2013

PubMed citations

1. Natural Variation in Fc Glycosylation of HIV-specific Antibodies Impacts Antiviral Activity. Ackerman, M.E., M. Crispin, X. Yu, K. Baruah, A.W. Boesch, D.J. Harvey, A.S. Dugast, E.L. Heizen, A. Ercan, I. Choi, H. Streeck, P.A. Nigrovic, C. Bailey-Kellogg, C. Scanlan, and G. Alter. The Journal of Clinical Investigation, 2013. [Epub ahead of print]. PMID[23563315].
[PubMed]. HIV_0329-041113.

2. Inhibition of HIV Type 1 Replication by Human T Lymphotropic Virus Types 1 and 2 Tax Proteins in Vitro. Barrios, C.S., L. Castillo, C.Z. Giam, L. Wu, and M.A. Beilke. AIDS Research and Human Retroviruses, 2013. [Epub ahead of print]. PMID[23464580].
[PubMed]. HIV_0329-041113.

3. Characteristics of IFITM, the Newly Identified IFN-inducible anti-HIV-1 Family Proteins. Chutiwitoonchai, N., M. Hiyoshi, Y. Hiyoshi-Yoshidomi, M. Hashimoto, K. Tokunaga, and S. Suzu. Microbes and Infection, 2013. 15(4): p. 280-290. PMID[23376165].
[PubMed]. HIV_0329-041113.

4. Synthesis and Biological Evaluation of a New Derivative of Bevirimat That Targets the Gag CA-SP1 Cleavage Site. Coric, P., S. Turcaud, F. Souquet, L. Briant, B. Gay, J. Royer, N. Chazal, and S. Bouaziz. European Journal of Medicinal Chemistry, 2013. 62: p. 453-465. PMID[23399723].
[PubMed]. HIV_0329-041113.

5. Inhibition of HIV-1 Transcription and Replication by a Newly Identified Cyclin T1 Splice Variant. Gao, G., X. Wu, J. Zhou, M. He, J.J. He, and D. Guo. The Journal of Biological Chemistry, 2013. [Epub ahead of print]. PMID[23569210].
[PubMed]. HIV_0329-041113.

6. Anti-HIV Efficacy and Biodistribution of Nucleoside Reverse Transcriptase Inhibitors Delivered as Squalenoylated Prodrug Nanoassemblies. Hillaireau, H., N. Dereuddre-Bosquet, R. Skanji, F. Bekkara-Aounallah, J. Caron, S. Lepetre, S. Argote, L. Bauduin, R. Yousfi, C. Rogez-Kreuz, D. Desmaele, B. Rousseau, R. Gref, K. Andrieux, P. Clayette, and P. Couvreur. Biomaterials, 2013. [Epub ahead of print]. PMID[23562054].
[PubMed]. HIV_0329-041113.

7. Conjugation of Cholesterol to HIV-1 Fusion Inhibitor C34 Increases Peptide-membrane Interactions Potentiating Its Action. Hollmann, A., P.M. Matos, M.T. Augusto, M.A. Castanho, and N.C. Santos. PloS One, 2013. 8(4): p. e60302. PMID[23565220].
[PubMed]. HIV_0329-041113.

8. Recent Progress in Biological Activities and Synthetic Methodologies of Pyrroloquinoxalines. Huang, A. and C. Ma. Mini Reviews in Medicinal Chemistry, 2013. 13(4): p. 607-616. PMID[23317497].
[PubMed]. HIV_0329-041113.

9. Discovery of a New HIV-1 Inhibitor Scaffold and Synthesis of Potential Prodrugs of Indazoles. Kim, S.H., B. Markovitz, R. Trovato, B.R. Murphy, H. Austin, A.J. Willardsen, V. Baichwal, S. Morham, and A. Bajji. Bioorganic & Medicinal Chemistry Letters, 2013. [Epub ahead of print]. PMID[23566519].
[PubMed]. HIV_0329-041113.

10. Cytotoxic, Antitopoisomerase II-alpha, and anti-HIV-1 Activities of Triterpenoids Isolated from Leaves and Twigs of Gardenia carinata. Kongkum, N., P. Tuchinda, M. Pohmakotr, V. Reutrakul, P. Piyachaturawat, S. Jariyawat, K. Suksen, R. Akkarawongsapat, J. Kasisit, and C. Napaswad. Journal of Natural Products, 2013. [Epub ahead of print]. PMID[23550966].
[PubMed]. HIV_0329-041113.

11. HIV Restriction by APOBEC3 in Humanized Mice. Krisko, J.F., F. Martinez-Torres, J.L. Foster, and J.V. Garcia. PLoS Pathogens, 2013. 9(3): p. e1003242. PMID[23555255].
[PubMed]. HIV_0329-041113.

12. Novel Pyridinone Derivatives as Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) with High Potency against NNRTI-resistant HIV-1 Strains. Li, A., Y. Ouyang, Z. Wang, Y. Cao, X. Liu, L. Ran, C. Li, L. Li, L. Zhang, K. Qiao, W. Xu, Y. Huang, Z. Zhang, C. Tian, Z. Liu, S. Jiang, Y. Shao, Y. Du, L. Ma, X. Wang, and J. Liu. Journal of Medicinal Chemistry, 2013. [Epub ahead of print]. PMID[23540737].
[PubMed]. HIV_0329-041113.

13. Synthesis and Biological Evaluation of Pyridazine Derivatives as Novel HIV-1 NNRTIs. Li, D., P. Zhan, H. Liu, C. Pannecouque, J. Balzarini, E. De Clercq, and X. Liu. Bioorganic & Medicinal Chemistry, 2013. 21(7): p. 2128-2134. PMID[23415090].
[PubMed]. HIV_0329-041113.

14. Efficient Synthesis of 3H,3'H-spiro[Benzofuran-2,1'-isobenzofuran]-3,3'-dione as Novel Skeletons Specifically for Influenza Virus Type B Inhibition. Malpani, Y., R. Achary, S.Y. Kim, H.C. Jeong, P. Kim, S.B. Han, M. Kim, C.K. Lee, J.N. Kim, and Y.S. Jung. European Journal of Medicinal Chemistry, 2013. 62: p. 534-544. PMID[23419738].
[PubMed]. HIV_0329-041113.

15. D316 Is Critical for the Enzymatic Activity and HIV-1 Restriction Potential of Human and Rhesus APOBEC3B. McDougle, R.M., J.F. Hultquist, A.C. Stabell, S.L. Sawyer, and R.S. Harris. Virology, 2013. [Epub ahead of print]. PMID[23542011].
[PubMed]. HIV_0329-041113.

16. Chimpanzee GB Virus C and GB Virus A E2 Envelope Glycoproteins Contain a Peptide Motif That Inhibits Human Immunodeficiency Virus Type 1 Replication in Human CD4+ T-cells. McLinden, J.H., J.T. Stapleton, D. Klinzman, K.K. Murthy, Q. Chang, T.M. Kaufman, N. Bhattarai, and J. Xiang. The Journal of General Virology, 2013. 94(Pt 4): p. 774-782. PMID[23288422].
[PubMed]. HIV_0329-041113.

17. Design and Synthesis of Biotin- or Alkyne-conjugated Photoaffinity Probes for Studying the Target Molecules of PD 404182. Mizuhara, T., S. Oishi, H. Ohno, K. Shimura, M. Matsuoka, and N. Fujii. Bioorganic & Medicinal Chemistry, 2013. 21(7): p. 2079-2087. PMID[23403297].
[PubMed]. HIV_0329-041113.

18. Sustained Inhibition of HIV-1 Replication by Conditional Expression of the E. coli-Derived Endoribonuclease MazF in CD4+ T Cells. Okamoto, M., H. Chono, Y. Kawano, N. Saito, H. Tsuda, K. Inoue, I. Kato, J. Mineno, and M. Baba. Human Gene Therapy Methods, 2013. [Epub ahead of print]. PMID[23442049].
[PubMed]. HIV_0329-041113.

19. Synthesis and Evaluation of Coumarin Derivatives as Potential Dual-action HIV-1 Protease and Reverse Transcriptase Inhibitors. Olomola, T.O., R. Klein, N. Mautsa, Y. Sayed, and P.T. Kaye. Bioorganic & Medicinal Chemistry, 2013. 21(7): p. 1964-1971. PMID[23415084].
[PubMed]. HIV_0329-041113.

20. Identification and Characterization of a Novel HIV-1 Nucleotide Competing RT Inhibitor Series. Rajotte, D., S. Tremblay, A. Pelletier, P. Salois, L. Bourgon, R. Coulombe, S. Mason, L. Lamorte, C. Sturino, and R. Bethell. Antimicrobial Agents and Chemotherapy, 2013. [Epub ahead of print]. PMID[23545531].
[PubMed]. HIV_0329-041113.

21. Side Chain Requirements for Affinity and Specificity in D5, an HIV-1 Antibody Derived from the VH1-69 Germline Segment. Stewart, A., J.S. Harrison, L.K. Regula, and J.R. Lai. BMC Biochemistry, 2013. 14(1): p. 9. PMID[23566198].
[PubMed]. HIV_0329-041113.

22. Expression, Purification and Identification of CtCVNH, a Novel anti-HIV (Human Immunodeficiency Virus) Protein from Ceratopteris thalictroides. Sun, J., Y. Su, and T. Wang. International Journal of Molecular Sciences, 2013. 14(4): p. 7506-7514. PMID[23567268].
[PubMed]. HIV_0329-041113.

23. Small Molecule Regulation of Protein Conformation by Binding in the Flap of HIV Protease. Tiefenbrunn, T., S. Forli, M.M. Baksh, M.W. Chang, M. Happer, Y.C. Lin, A.L. Perryman, J.K. Rhee, B.E. Torbett, A.J. Olson, J.H. Elder, M.G. Finn, and C.D. Stout. ACS Chemical Biology, 2013. [Epub ahead of print]. PMID[23540839].
[PubMed]. HIV_0329-041113.

24. Evaluation of HIV-1 Inhibition by Stereoisomers and Analogues of the Sesquiterpenoid Hydroquinone Peyssonol A. Treitler, D.S., Z. Li, M. Krystal, N.A. Meanwell, and S.A. Snyder. Bioorganic & Medicinal Chemistry Letters, 2013. 23(7): p. 2192-2196. PMID[23434230].
[PubMed]. HIV_0329-041113.

25. Selective Targeting of Dendritic Cell-specific Intercellular Adhesion Molecule-3-grabbing Nonintegrin (DC-SIGN) with Mannose-based Glycomimetics: Synthesis and Interaction Studies of Bis(benzylamide) Derivatives of a Pseudomannobioside. Varga, N., I. Sutkeviciute, C. Guzzi, J. McGeagh, I. Petit-Haertlein, S. Gugliotta, J. Weiser, J. Angulo, F. Fieschi, and A. Bernardi. Chemistry, 2013. 19(15): p. 4786-4797. PMID[23417900].
[PubMed]. HIV_0329-041113.

26. Improved Guanide Compounds Which Bind the CXCR4 Co-receptor and Inhibit HIV-1 Infection. Wilkinson, R.A., S.H. Pincus, K. Song, J.B. Shepard, A.J. Weaver, Jr., M.E. Labib, and M. Teintze. Bioorganic & Medicinal Chemistry Letters, 2013. 23(7): p. 2197-2201. PMID[23434419].
[PubMed]. HIV_0329-041113.

27. Digoxin Suppresses HIV-1 Replication by Altering Viral RNA Processing. Wong, R.W., A. Balachandran, M.A. Ostrowski, and A. Cochrane. PLoS Pathogens, 2013. 9(3): p. e1003241. PMID[23555254].
[PubMed]. HIV_0329-041113.

28. Sensitive and Continuous Screening of Inhibitors of beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) at Single SPR Chips. Yi, X., Y. Hao, N. Xia, J. Wang, M. Quintero, D. Li, and F. Zhou. Analytical Chemistry, 2013. 85(7): p. 3660-3666. PMID[23432118].
[PubMed]. HIV_0329-041113.

29. Protostane and Fusidane Triterpenes: A Mini-review. Zhao, M., T. Godecke, J. Gunn, J.A. Duan, and C.T. Che. Molecules, 2013. 18(4): p. 4054-4080. PMID[23563857].
[PubMed]. HIV_0329-041113.

30. Investigation of the Pharmacokinetic Interaction between Ritonavir and CMDCK, a New Non-nucleoside Reverse Transcriptase Inhibitor. Zhuang, X.M., G.L. Shen, M. Yuan, and H. Li. Drug Research, 2013. [Epub ahead of print]. PMID[23539429].
[PubMed]. HIV_0329-041113.

ISI Web of Knowledge Citations

31. Compartmentalization and Antiviral Effect of Efavirenz Metabolites in Blood Plasma, Seminal Plasma, and Cerebrospinal Fluid. Avery, L.B., J.L. VanAusdall, C.W. Hendrix, and N.N. Bumpus. Drug Metabolism and Disposition, 2013. 41(2): p. 422-429. ISI[000315352400022].
[WOS]. HIV_0329-041113.

32. Prostratin Exhibits Both Replication Enhancing and Inhibiting Effects on FIV Infection of Feline CD4(+) T-cells. Chan, C.N., E.L. McMonagle, M.J. Hosie, and B.J. Willett. Virus Research, 2013. 171(1): p. 121-128. ISI[000315607300015].
[WOS]. HIV_0329-041113.

33. Neglschisandrins E-F: Two New Lignans and Related Cytotoxic Lignans from Schisandra neglecta. Chen, M., X.M. Xu, B. Xu, P.P. Yang, Z.H. Liao, S.L. Morris-Natschke, K.H. Lee, and D.F. Chen. Molecules, 2013. 18(2): p. 2297-2306. ISI[000315400600073].
[WOS]. HIV_0329-041113.

34. The LEDGF/p75 Integrase Interaction, a Novel Target for anti-HIV Therapy (Vol 435, Pg 102, 2013). Christ, F. and Z. Debyser. Virology, 2013. 438(1): p. 50-50. ISI[000316036400007].
[WOS]. HIV_0329-041113.

35. IL-27 Inhibits HIV-1 Infection in Human Macrophages by Down-regulating Host Factor SPTBN1 During Monocyte to Macrophage Differentiation. Dai, L., K.B. Lidie, Q. Chen, J.W. Adelsberger, X. Zheng, D.W. Huang, J. Yang, R.A. Lempicki, T. Rehman, R.L. Dewar, Y.M. Wang, R.L. Hornung, K.A. Canizales, S.J. Lockett, H.C. Lane, and T. Imamichi. Journal of Experimental Medicine, 2013. 210(3): p. 517-534. ISI[000315997000008].
[WOS]. HIV_0329-041113.

36. The Potential of Sutherlandia frutescens for Herb-drug Interaction. Fasinu, P.S., H. Gutmann, H. Schiller, A.D. James, P.J. Bouic, and B. Rosenkranz. Drug Metabolism and Disposition, 2013. 41(2): p. 488-497. ISI[000315352400029].
[WOS]. HIV_0329-041113.

37. HIV-1 Viral Infectivity Factor (Vif) Alters Processive Single-stranded DNA Scanning of the Retroviral Restriction Factor APOBEC3G. Feng, Y.Q., R.P. Love, and L. Chelico. Journal of Biological Chemistry, 2013. 288(9): p. 6083-6094. ISI[000315820700006].
[WOS]. HIV_0329-041113.

38. Insights into the Mechanism of Drug Resistance: X-ray Structure Analysis of Multi-drug Resistant HIV-1 Protease Ritonavir Complex. Liu, Z.G., R.S. Yedidi, Y. Wang, T.G. Dewdney, S.J. Reiter, J.S. Brunzelle, I.A. Kovari, and L.C. Kovari. Biochemical and Biophysical Research Communications, 2013. 431(2): p. 232-238. ISI[000315325300021].
[WOS]. HIV_0329-041113.

39. d(GGGT)(4) and r(GGGU)(4) Are Both HIV-1 Inhibitors and Interleukin-6 Receptor Aptamers. Magbanua, E., T. Zivkovic, B. Hansen, N. Beschorner, C. Meyer, I. Lorenzen, J. Grotzinger, J. Hauber, A.E. Torda, G. Mayer, S. Rose-John, and U. Hahn. RNA Biology, 2013. 10(2): p. 216-227. ISI[000315591500008].
[WOS]. HIV_0329-041113.

40. Structure of a Glycomimetic Ligand in the Carbohydrate Recognition Domain of C-type Lectin DC-SIGN. Structural Requirements for Selectivity and Ligand Design. Thepaut, M., C. Guzzi, I. Sutkeviciute, S. Sattin, R. Ribeiro-Viana, N. Varga, E. Chabrol, J. Rojo, A. Bernardi, J. Angulo, P.M. Nieto, and F. Fieschi. Journal of the American Chemical Society, 2013. 135(7): p. 2518-2529. ISI[000315373000031].
[WOS]. HIV_0329-041113.

41. Evaluation of a 13-Hexyl-berberine Hydrochloride Topical Gel Formulation. Wei, H.L., S.Q. Wang, F. Xu, L.F. Xu, J.R. Zheng, and Y. Chen. Drug Development and Industrial Pharmacy, 2013. 39(4): p. 534-539. ISI[000315414300005].
[WOS]. HIV_0329-041113.